BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BP2202 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BP2202\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07667868-3431@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BP2202: Phase 1 readout est. (NCT07667868)
DESCRIPTION:BP2202\, phase 1\, Multiple Myeloma.\nStudy: A Phase I\, Open-l
 abel\, Multicenter Study to Evaluate the Safety and Tolerability of BP2202
  in Patients With Relapsed/Refractory Multiple Myeloma\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/bp2202#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07667868
URL:https://assetmemo.bio/drug/bp2202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
